Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
Chemical Formula
-
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis
Associated Therapies
-

Botox Injections for Patients With Persistent Facial Pain

Phase 2
Completed
Conditions
Interventions
First Posted Date
2018-03-12
Last Posted Date
2021-12-17
Lead Sponsor
Norwegian University of Science and Technology
Target Recruit Count
31
Registration Number
NCT03462290
Locations
🇳🇴

Department of Neuroscience, Faculty of Medicine and Health Science, NTNU, Trondheim, Norway

Botox Instead of Strabismus Surgery (BISS)

First Posted Date
2018-03-08
Last Posted Date
2023-11-07
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Target Recruit Count
63
Registration Number
NCT03459092
Locations
🇨🇭

Basel University Hopital, Basel, Switzerland

🇨🇭

Kantonsspital St. Gallen, Saint Gallen, Switzerland

🇨🇭

Bern University Hospital, Bern, Switzerland

and more 5 locations

Topical Aluminium Chloride vs OnabotulinumtoxinA Intradermal Injections in Residual Limb Hyperhidrosis (Lower Limbs)

First Posted Date
2018-02-15
Last Posted Date
2021-04-28
Lead Sponsor
Direction Centrale du Service de Santé des Armées
Target Recruit Count
54
Registration Number
NCT03433859
Locations
🇫🇷

Les Capucins, Angers, France

🇫🇷

Hopital Percy, Clamart, France

🇫🇷

Centre La Tourmaline, Saint Herblain, France

and more 6 locations

Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines

Phase 3
Completed
Conditions
Interventions
First Posted Date
2018-01-23
Last Posted Date
2022-04-15
Lead Sponsor
Hugel
Target Recruit Count
240
Registration Number
NCT03408236
Locations
🇰🇷

Hugel, Seoul, Korea, Republic of

(Botox) Mechanisms of Action in Altering the Molecular Environment in Which Pain Fibers Exist

Phase 4
Completed
Conditions
Interventions
First Posted Date
2017-12-21
Last Posted Date
2024-03-13
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
49
Registration Number
NCT03381261
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Functional Effects of Botox on the Brain Using MRS and fMRI

Phase 4
Completed
Conditions
Interventions
First Posted Date
2017-12-14
Last Posted Date
2020-06-01
Lead Sponsor
University of California, Irvine
Target Recruit Count
10
Registration Number
NCT03373162
Locations
🇺🇸

University of California, Irvine, Irvine, California, United States

DWP450 Treatment in Subjects With Benign Masseteric Hypertrophy

First Posted Date
2017-12-12
Last Posted Date
2017-12-12
Lead Sponsor
Daewoong Pharmaceutical Co. LTD.
Target Recruit Count
98
Registration Number
NCT03369990

Improvement on GMFCS Level of Patients With Cerebral Palsy Treated by Repeated Botulinum Toxin-A

Completed
Conditions
First Posted Date
2017-11-17
Last Posted Date
2018-11-30
Lead Sponsor
Kocaeli University
Target Recruit Count
503
Registration Number
NCT03344952
Locations
🇹🇷

Kocaeli University, Kocaeli, Turkey

The Effect of Botulinum Toxin A on Headache Attributed to TMD

Early Phase 1
Completed
Conditions
Interventions
First Posted Date
2017-11-17
Last Posted Date
2022-10-04
Lead Sponsor
State University of New York at Buffalo
Target Recruit Count
20
Registration Number
NCT03346252
Locations
🇺🇸

University at Buffalo, Buffalo, New York, United States

MEDITOXIN® in Treatment of Crow's Feet Line

Phase 3
Completed
Conditions
Interventions
First Posted Date
2017-10-23
Last Posted Date
2019-03-27
Lead Sponsor
Medy-Tox
Target Recruit Count
250
Registration Number
NCT03317574
Locations
🇰🇷

Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath